| 1. |
- Johansson, Ida, et al.
(författare)
-
Review of regional energy efficiency policies towards industrial SMEs from within Europe
- 2020
-
Ingår i: Eceee Industrial Summer Study Proceedings. - 9789198387865 ; , s. 15-22
-
Konferensbidrag (refereegranskat)abstract
- Industrial SMEs represent 99 % or more of the total number of companies in most countries, and one-third of the total industrial energy use. Despite this, industrial SMEs have not received much attention both in terms of research and policies. The scientific papers published in the field covers national energy efficiency policy programs and evaluations of these, while scientific studies of regional policy programs are few. SMEs in general have a low capacity to work on improved energy efficiency, and the term SME is generally too vague to provide any guidance on how to design public policy programs. Administrative policies might be a sound approach for medium-sized enterprises but for small-sized enterprises the administrative policies could be less effective. For medium-sized and energy-intensive industrial SMEs, economic and/or regulatory incentives are important, while for small-sized and non-energy intensive industrial SMEs there is a need for a more supportive approach. The aim of this paper is to provide an overview of existing regional energy efficiency policies targeting industrial SMEs in seven selected EU member states. This overview also provides an insight of the type of policy approach (informative, economic or administrative) that is most commonly used in regional policy activities.
|
|
| 2. |
- Johansson, Madeleine, et al.
(författare)
-
Pharmacometabolomic Profiling Of The General Population: Relation Of Active Metabolite Levels To Cardiovascular Risk Factor Control And Manifest Atherosclerosis
- 2021
-
Ingår i: Circulation. - 1524-4539. ; 144:suppl_1
-
Konferensbidrag (refereegranskat)abstract
- Introduction: The use of medications in the general population has increased over time. Information on active metabolite concentrations for common drugs in the general population is limited. Recent advances in metabolomic technologies have made high-throughput profiling of many active metabolites in large epidemiological cohorts increasingly feasible.Aim: 1. Prospective assessment of the proportion of measurable active metabolite levels of major drugs in the general population using mass spectrometry. 2. Relation of cardiovascular (CV) drugs with inadequate risk factor control and CV disease.Methods: Assessment of CV risk factors by coronary CT angiography and carotid ultrasound imaging in a large prospective cohort of 6,251 individuals randomly selected from the general population in Malmö, Sweden (age 50-64 years). Untargeted metabolomic profiling of fasting plasma was performed by Metabolon, USA in a random subset of 3,986 subjects.Results: Intake of at least one prescribed drug was reported in 1840 subjects (46%). Combination drugs were reported in 249 subjects (6%). The most common drug classes reported were lipid-lowering (n=369, 9% of which most were statins), beta blockers (n=307, 8%), ARB (n=272, 7%), and ACE inhibitors (268, 7%), followed by levothyroxine, CCB, antidepressants, glucocorticoids, PPI, antidiabetic, bronchodilators and diuretics. For major CV drugs, detectable active metabolite levels ranged from 54% (atorvastatin and enalapril) to 96% (metoprolol and metformin). Non-detectable levels of lipid-lowering, antihypertensive, and antidiabetic drugs were associated with higher LDL, cholesterol, BP and glucose, although only antidiabetic drugs were significant (p<0.05). Non-detectable levels of lipid-lowering and antihypertensive drugs were also non-significantly associated with increased coronary calcium and carotid plaque.Conclusion: Our study provides an overview of the distribution of common drugs with detectable levels in a contemporary Swedish population. Pharmacometabolomic profiling revealed that non-measurable levels of common CV drugs were associated with lower risk factor control and non-significant trends towards more atherosclerotic disease by imaging in a substantial number of subjects.
|
|
